Survival trends over 20 years in patients with advanced cholangiocarcinoma : Results from a national retrospective analysis of 922 cases in Italy
Copyright © 2023 Casadei-Gardini, Leone, Brandi, Scartozzi, Silvestris, Santini, Faloppi, Aglietta, Satolli, Rizzo, Lonardi, Aprile and Fornaro..
Cholangiocarcinoma is a rare group of tumors that involve the hepatic biliary tree. Prognosis for patients with cholangiocarcinoma remains dismal. Herein, we present survival trends over a long time period spanning almost 20 years in patients with advanced cholangiocarcinoma receiving systemic chemotherapy. We retrospectively analyzed a large multicenter dataset of cholangiocarcinoma outpatients evaluated in 14 centers within the Cholangiocarcinoma Italian Group Onlus (Gruppo Italiano Colangiocarcinoma Onlus, G.I.C.O.) between 2000 and 2017 (first-line), and 2002 and 2017 (second-line). Three time periods were considered: 2000-2009, 2010-2013, and 2014-2017. A total of 922 patients (51.19% male) with cholangiocarcinoma undergoing first-line therapy were evaluated. The median durations of follow-up for progression-free survival (PFS) and overall survival (OS) were 37 and 57 months, respectively. PFS at 12 months in the three periods of starting first-line therapy was similar, ranging from 11.71% to 15.25%. OS at 12 months progressively improved (38.30%, 44.61% and 49.52%, respectively), although the differences were not statistically significant after adjusting for age, disease status, and primary tumor site. A total of 410 patients (48.5% male) underwent second-line chemotherapy. The median durations of follow-up for PFS and OS were 47.6 and 41.90 months, respectively. An OS of 24.3%, 32.3%, and 33.1% was observed in 2002-2009, 2010-2013, and 2014-2017, respectively. Despite incremental benefits across years, our clinical experience confirms that modest overall advances have been achieved with first- and second-line chemotherapy in advanced cholangiocarcinoma. Efforts should focus on the identification of patients who derive the greatest benefit from treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in oncology - 13(2023) vom: 17., Seite 1128930 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Casadei-Gardini, Andrea [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Advanced cholangiocarcinoma |
|---|
| Anmerkungen: |
Date Revised 25.04.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fonc.2023.1128930 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355948605 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355948605 | ||
| 003 | DE-627 | ||
| 005 | 20231226210300.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fonc.2023.1128930 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1186.xml |
| 035 | |a (DE-627)NLM355948605 | ||
| 035 | |a (NLM)37091141 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Casadei-Gardini, Andrea |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Survival trends over 20 years in patients with advanced cholangiocarcinoma |b Results from a national retrospective analysis of 922 cases in Italy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.04.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2023 Casadei-Gardini, Leone, Brandi, Scartozzi, Silvestris, Santini, Faloppi, Aglietta, Satolli, Rizzo, Lonardi, Aprile and Fornaro. | ||
| 520 | |a Cholangiocarcinoma is a rare group of tumors that involve the hepatic biliary tree. Prognosis for patients with cholangiocarcinoma remains dismal. Herein, we present survival trends over a long time period spanning almost 20 years in patients with advanced cholangiocarcinoma receiving systemic chemotherapy. We retrospectively analyzed a large multicenter dataset of cholangiocarcinoma outpatients evaluated in 14 centers within the Cholangiocarcinoma Italian Group Onlus (Gruppo Italiano Colangiocarcinoma Onlus, G.I.C.O.) between 2000 and 2017 (first-line), and 2002 and 2017 (second-line). Three time periods were considered: 2000-2009, 2010-2013, and 2014-2017. A total of 922 patients (51.19% male) with cholangiocarcinoma undergoing first-line therapy were evaluated. The median durations of follow-up for progression-free survival (PFS) and overall survival (OS) were 37 and 57 months, respectively. PFS at 12 months in the three periods of starting first-line therapy was similar, ranging from 11.71% to 15.25%. OS at 12 months progressively improved (38.30%, 44.61% and 49.52%, respectively), although the differences were not statistically significant after adjusting for age, disease status, and primary tumor site. A total of 410 patients (48.5% male) underwent second-line chemotherapy. The median durations of follow-up for PFS and OS were 47.6 and 41.90 months, respectively. An OS of 24.3%, 32.3%, and 33.1% was observed in 2002-2009, 2010-2013, and 2014-2017, respectively. Despite incremental benefits across years, our clinical experience confirms that modest overall advances have been achieved with first- and second-line chemotherapy in advanced cholangiocarcinoma. Efforts should focus on the identification of patients who derive the greatest benefit from treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Italy | |
| 650 | 4 | |a advanced cholangiocarcinoma | |
| 650 | 4 | |a outcomes | |
| 650 | 4 | |a retrospective study | |
| 650 | 4 | |a survival | |
| 700 | 1 | |a Leone, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Brandi, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Scartozzi, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Silvestris, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Santini, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Faloppi, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Aglietta, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Satolli, Maria Antonietta |e verfasserin |4 aut | |
| 700 | 1 | |a Rizzo, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Lonardi, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Aprile, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Fornaro, Lorenzo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in oncology |d 2011 |g 13(2023) vom: 17., Seite 1128930 |w (DE-627)NLM218189583 |x 2234-943X |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g day:17 |g pages:1128930 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fonc.2023.1128930 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |b 17 |h 1128930 | ||